期刊
VACCINES
卷 9, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/vaccines9091033
关键词
COVID-19; mRNA vaccine; SARS-CoV-2; stability; storage
In response to the emergence of COVID-19, mRNA-based vaccines by Moderna and BioNTech/Pfizer have been identified as the most effective ones. However, the global use of these vaccines is limited by ultracold storage requirements. Therefore, finding strategies to increase stability of mRNA-based vaccines in relatively higher temperatures is crucial to address the current global pandemic and upcoming new waves.
In December 2019, a new and highly pathogenic coronavirus emerged-coronavirus disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), quickly spread throughout the world. In response to this global pandemic, a few vaccines were allowed for emergency use, beginning in November 2020, of which the mRNA-based vaccines by Moderna (Moderna, Cambridge, MA, USA) and BioNTech (BioTech, Mainz, Germany)/Pfizer (Pfizer, New York, NY, USA) have been identified as the most effective ones. The mRNA platform allowed rapid development of vaccines, but their global use is limited by ultracold storage requirements. Most resource-poor countries do not have cold chain storage to execute mass vaccination. Therefore, determining strategies to increase stability of mRNA-based vaccines in relatively higher temperatures can be a game changer to address the current global pandemic and upcoming new waves. In this review, we summarized the current research strategies to enhance stability of the RNA vaccine delivery system.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据